Ovid Therapeutics Inc. cotiza a 2.41 USD y tiene una capitalización bursátil de $471M. En los últimos 12 meses ha facturado $2M con un margen de flujo de caja libre del -528.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.12 | $0.06 |
| Estimado | $-0.09 | $-0.10 | $-0.11 | $-0.10 |
| Sorpresa | — | — | -9.1% | +160.0% |
| Métrica | OVID | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -585.2% | -38.6% | -546.6% |
| Net Margin | -240.1% | -33.6% | -206.6% |
| FCF Margin | -528.6% | -13.9% | -514.7% |
| ROE | -13.3% | -40.4% | +27.1% |
| ROA | -11.5% | -32.0% | +20.5% |
| Current Ratio | 8.97 | 2.84 | +6.13 |
| Debt / Equity | — | 0.28 | — |